title: Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.
abstract: Allogenic hematopoietic cell transplantation (alloHCT) is currently the only curative treatment option for patients with sickle cell disease. Alemtuzumab is a monoclonal antibody directed against CD52 positive cells used in myeloablative conditioning regimens for alloHCT. Its use has been associated with development of autoimmune disease in adult patients with rheumatologic conditions. We report on three cases of new onset autoimmune thyroid disease after alloHCT treatment with alemtuzumab in pediatric patients with sickle cell disease.
authors.affiliation: Department of Pediatrics, Columbia University Medical Center, New York, NY.
authors.forename: Kristen M
authors.initials: KM
authors.lastname: Williams
authors.forename: Danielle
authors.initials: D
authors.lastname: Dietzen
authors.forename: Abeer A
authors.initials: AA
authors.lastname: Hassoun
authors.forename: Ilene
authors.initials: I
authors.lastname: Fennoy
authors.forename: Monica
authors.initials: M
authors.lastname: Bhatia
mesh_terms: D000293:Adolescent; D000328:Adult; D000074323:Alemtuzumab; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000628:therapy; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000188:drug therapy / Q000209:etiology*; D050031:Hashimoto Disease / Q000188:drug therapy / Q000209:etiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D013967:Thyroiditis, Autoimmune / Q000188:drug therapy / Q000209:etiology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074323:Alemtuzumab
keywords: alemtuzumab; autoimmunity; sickle cell disease; stem cell transplant; thyroid dysfunction